April 26, 2018 VACCIBODY AS ANNOUNCES STRONG KILLER T CELL RESPONSES (CD8+) in VB10.16 VACCINATED PATIENTS FURTHER STRENGTHENING THE STRONG POTENTIAL OF THEIR VACCINE TECHNOLOGY PLATFORM; PRESENTING AT EUROPEAN NEOANTIGEN SUMMIT AMSTERDAM
Vaccibody AS, a clinical-stage company focused on developing cancer vaccines to target solid tumors, today announces clinical data demonstrating vaccine-induced killer T cell responses (CD8+) in patients in their clinical program to treat precancerous cervical intraepithelial neoplasia (CIN) 2/3 lesions (VB C-01). President and Chief Scientific Officer, Agnete Fredriksen, will present the data at the European Neoantigen Summit this week.
The phase IIa part of Vaccibody´s VB C-01 study with VB10.16 immunotherapy was fully recruited in December 2017. We here report immunogenicity data for the first 10 patients in phase IIa, showing vaccine-induced immune responses in 10 out of 10 vaccinated patients. In total, 26 patients in the phase I/IIa study have now been tested of which 25 (96 %) elicited an increased immune response after vaccination.
Further analysis in selected patients detected both killer T cells (CD8+) and helper T cell responses (CD4+) in vaccinated patients ex vivo, and both cell types produced proinflammatory cytokines. Strong CD8+ T cell responses were verified by multimer analysis. These data confirm in a clinical setting the unique ability of the Vaccibody DNA vaccine platform to induce strong killer T cell responses.
Agnete Fredriksen, President & Chief Scientific Officer of Vaccibody said, “We are very pleased that we now can present data showing activation of CD8+ killer T cell responses in patients vaccinated with our lead compound VB10.16. The new clinical immunogenicity data clearly demonstrates the ability of the Vaccibody vaccine technology to elicit strong immune responses, as we observed increased immune response in 25 out of the 26 vaccinated patients analysed so far. We know that CD8+ T cell have the potential to directly kill cancer cells and we look forward to study this further. With these promising immunogenicity data from the HPV trial in combination with the unique responses dominated by CD8+ T cells observed in our preclinical neoantigen studies, we are also eager to follow the responses in the neoantigen clinical trial, which has already recruited its first patient”.
About Vaccibody AS
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. Vaccibody is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. Vaccibody’s front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), which is now fully enrolled, evaluates the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).
Martin Bonde CEO
Oslo Research Park
Gaustadalléen 21 0349 Oslo, Norway